SCHEMBL4149924

SCHEMBL4149924

CCOC(=O)C1CCN(C(=O)OC(C)(C)C)CC1c1ccc(Cl)c(Cl)c1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.47
SLC6A4 P31645 2/20 0.47
SLC6A3 Q01959 2/20 0.47
PDE4B Q07343 6/20 0.47
SLC6A2 P23975 1/20 0.45
TACR3 P29371 1/20 0.44
PDE4A P27815 1/20 0.44
PDE4C Q08493 1/20 0.44
PDE4D Q08499 1/20 0.44
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MAPT P10636 1/20 0.42
MAPK1 P28482 1/20 0.42
HTT P42858 1/20 0.42
STS P08842 1/20 0.41
TP53 P04637 1/20 0.41
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4149929 1.00 TSHR (0.47) TSHRSLC6A4SLC6A3PDE4BSLC6A2
SCHEMBL13400256 0.92 SLC6A4 (0.53) TSHRSLC6A4SLC6A3PDE4BSLC6A2
SCHEMBL4154880 0.89 PDE4B (0.60) SLC6A4SLC6A3PDE4BSLC6A2
SCHEMBL4000213 0.89 PDE4B (0.60) SLC6A4SLC6A3PDE4BSLC6A2
SCHEMBL4141590 0.86 PDE4B (0.52) SLC6A4SLC6A3PDE4BSLC6A2TACR3
SCHEMBL1972927 0.86 PDE4B (0.52) SLC6A4SLC6A3PDE4BSLC6A2TACR3
SCHEMBL4159759 0.86 PDE4B (0.52) SLC6A4SLC6A3PDE4BSLC6A2TACR3
SCHEMBL3012199 0.86 PDE4B (0.47) PDE4BTACR3PDE4APDE4CPDE4D
SCHEMBL7914442 0.86 PDE4B (0.47) PDE4BTACR3PDE4APDE4CPDE4D
SCHEMBL3012198 0.86 PDE4B (0.47) PDE4BTACR3PDE4APDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8470816-B2 Nitrogen-containing heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-25 US disclosed
US-20090156572-A1 Nitrogen-containing heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED 2009-06-18 US disclosed
WO-2008133344-A2 PIPERIDINE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-11-06 WO disclosed
US-20080275085-A1 Piperidine derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275085-A1 Piperidine derivative and use thereof TACR2, TACR1, PRLHR TSHR 71/4885SLC6A4 432/4885SLC6A3 371/4885
US-20090156572-A1 Nitrogen-containing heterocyclic compound and use thereof NTSR2, NTSR1, HNMT TSHR 396/4885SLC6A4 271/4885SLC6A3 324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.